

COSTS OF DEMENTIA IN LOW-AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW

Angeladine Kenne Malaha, Clémence Thébaut, Dayna Achille, Pierre-Marie Preux, Maëlenn Guerchet

▶ To cite this version:

Angeladine Kenne Malaha, Clémence Thébaut, Dayna Achille, Pierre-Marie Preux, Maëlenn Guerchet. COSTS OF DEMENTIA IN LOW-AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC RE-VIEW. Journal of Alzheimer's Disease, 2022, pp.1-14. 10.3233/JAD-220239 . ird-03869701

HAL Id: ird-03869701 https://ird.hal.science/ird-03869701

Submitted on 24 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1	COSTS OF DEMENTIA IN LOW- AND MIDDLE-INCOME COUNTRIES: A
2	SYSTEMATIC REVIEW
3	Angeladine Kenne Malaha ^a , Clémence Thébaut ^{a,b} , Dayna Achille ^a , Pierre-Marie
4	Preux ^{a,c} , Maëlenn Guerchet ^{a*}
5	
6	(a) Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT -
7	Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and
8	Tropical Neurology, Omega Health, Limoges, France
9	(b) Leda-Legos, PSL Research University, Paris Dauphine University, Paris, France
10	(c) CHU, Centre d'Epidémiologie de Biostatistique et de Méthodologie de la
11	Recherche, Limoges, France
12	
13	Running title: Dementia costs in low/middle-income countries
14	
15	*Corresponding author:
16	Maëlenn Guerchet, PhD
17	Inserm U1094, IRD UMR270 – EpiMaCT
18	Faculty of Medicine
19	2 rue du Dr Marcland, 87025 Limoges Cedex
20	Tél. : 05 55 43 58 20 - Fax : 05 55 43 58 21
21	Email : maelenn.guerchet@ird.fr

22 ABSTRACT

23 Background

The proportion of people living with dementia in low- and middle-income countries (LMICs) is expected to reach 71% by 2050. Appraising the economic burden of the disease may contribute to strategic policy planning.

27 Objective

To review studies conducted on the costs of dementia in LMICs, describe their methodology and summarize available costs estimates.

30 Methods

Systematic review, including a search of health, economics and social science bibliographic databases. No date or language restrictions were applied. All studies with a direct measure of the costs of dementia care were included.

34 Results

Of the 6,843 publications reviewed, 17 studies from 11 LMICs were included. Costs of dementia tended to increase with the severity of the disease. Medical costs were greater in the mild stage, while social and informal care costs were highest in the moderate and severe stages. Annual cost estimates per patient ranged from PPP\$131.0 to PPP\$31,188.8 for medical costs; from PPP\$16.1 to PPP\$10,581.7 for social care services and from PPP\$140.0 to PPP\$25,798 for informal care. Overall, dementia care can cost from PPP\$479.0 to PPP\$66,143.6 per year for a single patient.

42 Conclusion

Few studies have been conducted on the costs of dementia in LMICs, and none so far in Africa. There seems to be a need to provide accurate data on the burden of disease in these countries to guide public health policies in the coming decades.

- **Keywords:** Dementia; Alzheimer's disease; Cost of illness; Disease Burden;
- 47 Systematic review; Low-Income; Middle-Income.

48 **INTRODUCTION**

An estimated 57.4 million people worldwide were living with dementia in 2019. This number is expected to increase to 152.8 million by 2050, mainly due to population growth and ageing [1]. According to the World Health Organization (WHO), much of this increase will be in low- and middle-income countries (LMICs) where 60% of people with dementia (PWD) already live. This figure could rise to 71% in 2050 [1,2].

In the latest Global status report on the public health response to dementia, the annual 54 global cost of dementia has been estimated at US\$ 1.3 trillion in 2019, up from US\$818 55 billion in 2015. This figure is expected to reach US\$1.7 trillion by 2050 [3,4]. In LMICs, 56 these costs amount to about US\$341.0 billion, divided into US\$59.4 billion for direct 57 medical costs, US\$61.0 billion for direct social sector costs and US\$220.6 billion for 58 informal care. For high-income countries (HICs), these costs are US\$972.3 billion, 59 US\$153.9 billion, US\$387.7 billion and US\$430.8 billion respectively [3]. Therefore, 60 informal care costs account for half (49.6%) of the total cost of dementia worldwide, 61 with 64.7% in LMICs and 44.3% in HICs, while evidence show that about 84% of PWD 62 worldwide live with their families [3,5]. 63

Cost-of-illness (COI) studies aim to assess the economic burden of health problems 64 on the whole population [6-8]. They are useful for determining the current status of a 65 disease care system and its costs, as well as for assessing changes over time or 66 between diseases, to assist in public health decision-making [8,9]. However, 67 evaluating the costs of dementia remains a complex exercise. It requires distinguishing 68 between costs categories, identifying costs attributable to the disease, managing 69 70 different data sources, and conducting accurate analyses [10,11]. A few studies have estimated the global costs of dementia [4,5,10–12]. The 2010 and 2015 reports on the 71 economic impact of Alzheimer's disease [4,12] used the annual cost of dementia per 72

person in each country, where available, computed with the projected number of PWD living in the country. Analyses also included imputations and a set of assumptions for countries with missing or insufficient data. For LMICs with very little primary data, authors reported using data from neighboring or comparable countries, gross domestic product, and health care expenditure per capita [4,12], which led to less reliable or accurate estimates for these regions.

As mentioned in the Alzheimer's Disease International report on dementia in sub-Saharan Africa, the lack of original cost data remains the weakest link in assessing the burden of dementia in the region [13]. Therefore, this review was conducted to identify costs of dementia studies conducted to date in LMICs with the aim of describing their methods, summarizing the available data and identifying the challenges of such studies in resource-limited settings.

85 MATERIALS AND METHODS

We conducted a systematic review on the costs of dementia in LMICs and the methodologies used for their evaluation. All original research articles from studies conducted in LMICs (according to World Bank classification on January 1st 2020) and presenting a cost evaluation of any aspect of dementia care were considered. Disease cost categories are generally related to direct medical (i.e related to the medical care system), social care (i.e formal services provided outside of the medical care system) and informal care (related to the time spent by non-paid relatives on care) [12].

93 Search strategy

Bibliographic databases on health, health economics and social sciences were
searched: Pubmed/Medline, Embase, Global health, PsycINFO, PsycARTICLES (via
OVID), Web of science and Econlit. The main grey literature resources in the health

field were also searched (Greylit, ProQuest, Georgetown University resource and 97 Google scholar). No language or date restrictions were applied. Search strategies 98 consisted of combinations of different keywords related to the disease (dementia, 99 Alzheimer's, cognitive disorder / impairment), costs (cost, valuation, expenses, and 100 burden) and settings (low-income, middle-income, resource limited, developing 101 country and, the list of the 137 LMICs countries (according to the World Bank on 102 January 1st, 2020 [14])). Specific equations for each database as searched on March 103 2nd 2020 are presented in Supplementary material 1. An updated search using the 104 same strategy was conducted on December 28th 2021 to identify potential new studies 105 106 of interest.

107 Studies selection

Results obtained from the searches on the different bibliographic databases were 108 imported and processed using the Rayyan QCRI tool [15]. In a first step, duplicates 109 were removed. Then, following a blind selection method, two investigators (AKM and 110 DA) assessed the eligibility of the selected articles based on titles and abstracts. The 111 proportion of agreement between the two investigators was measured; conflicting 112 articles at this stage were all retained for the next stage. Full texts of selected 113 references were retrieved, and the corresponding authors were contacted to request 114 the manuscript when those were not available. Full-texts were then evaluated by the 115 same two investigators (AKM and DA) for the final inclusion decision. Conflicting 116 articles were discussed and the inclusion decision was made with a third investigator 117 118 (MG or CT).

Protocols, reviews and meta-analyses were not included, but were examined to identify any relevant study for consideration. In addition, references of selected articles were checked. For publications in languages other than English and French (those in

Spanish, Portuguese and Chinese), collaborators were asked to provide a translation
and/or description of the studies in order to make a decision on eligibility and to extract
the data of interest.

During the selection process, articles were excluded according to the Population, 125 Intervention, Comparator and Outcome (PICO) framework. Laboratory experiments 126 (i.e fundamental research on Alzheimer's Disease / dementia, including in-vitro studies 127 and studies in non-human populations), studies not addressing dementia care, and 128 studies conducted outside LMICs were considered as wrong population. Wrong 129 publication types included narrative review, meta-analysis, overview article, letter to 130 131 the editor and commentaries. Studies without a direct measure of dementia cost were 132 accounted as wrong outcomes. Studies for which the full-text was not retrieved despite multiple searches and contact with the authors were also excluded. 133

134 Quality assessment

Although various guidelines have been published for assessing the quality of economic evaluation in health care [16,17], they mainly focus on cost-effectiveness analyses. In the absence of a standard instrument to evaluate cost-of-illness studies, we assessed the quality of articles using a checklist, derived from the guide proposed by Larg and Moss [7] and the checklist developed by Kline-Budde et al. [18] for their review on bipolar disorders. Full description of the quality assessment criteria used is provided in Supplementary material 2.

142 Data processing and analysis

Full-texts were reviewed and data extracted using a standardized extraction grid developed in Epi Info 7 and Microsoft Excel®. Data were collected on study design, population characteristics and costing methods. Particular attention was paid to the

costing perspective (i.e the point of view from which costs are considered). Studies 146 may measure costs to a health care system, a third-party payers, commercial sectors, 147 government or participants and their families [19]. In this review, the perspective was 148 collected as specified in the original article. Instruments used to collect and valuate 149 health resource utilization were also explored, to check the use of standard validated 150 tools such as the Resource Utilization in Dementia (RUD) instrument [20] or 151 questionnaires specifically designed by researchers for the purpose of their study. 152 Costing approaches used to value informal care time were also assessed. Various 153 methods for the valuation of informal care are available in the literature. On the one 154 155 hand, there are revealed preference methods that are based on real-life decision data: 1) the opportunity cost method, which aims to estimate the cost of the opportunity to 156 earn income or partake in leisure activities that an individual forgoes when engaging 157 in informal care; 2) the replacement cost, or proxy good method, which assigns costs 158 based on the market value that the care services would cost if they were provided by 159 a professional provider. On the other hand, stated preference studies obtain value by 160 asking respondents directly what economic value they attach to informal care through 161 contingent valuation or conjoint analysis [21,22]. 162

163 When information was not presented in the original article as required for extraction, available data were converted to the accurate value and unit. For example, all sex 164 ratios and gender figures were converted to male percentage. When data was not 165 available or presented in a non-transformable format, it was considered missing. When 166 summarizing data, weighting was done using the representativeness of each category 167 in the total sample. For example, to calculate the total medical costs of a given study 168 presented by disease severity, the proportion of participants in each stage was taken 169 into account. Monetary data were converted into local currency unit (LCU) using the 170

exchange rate provided by the authors. Where these were not available, we used exchange rates provided by the World Bank for the country in the year of the study cost [23]. Costs were then updated to their 2020 value using country-specific deflators provided by the World Bank [24], and converted to 2020 dollar purchasing power parities (PPP) using official conversion factors [25].

All costs were collected under the original items as provided by studies. They were then grouped into a dozen of health resource services and finally into the three main cost-of-illness categories (i.e. direct medical care, social care and informal care). Some studies presented costs results directly in the three main categories which does not allow for a desegregated presentation; these are presented only in total costs descriptions.

182 The protocol of this systematic review was registered in PROSPERO (registration 183 number CRD42020169898) before data extraction began.

184 **RESULTS**

From the initial search, 11,168 publications were identified and extracted from the 185 databases. Details are presented in Supplementary material 3. Figure 1 shows the 186 187 articles selection flow chart according to updated PRISMA guidelines [26]. After eliminating duplicates, 6,843 publications were assessed for eligibility. Of the 91 188 189 eligible articles, 74 full-text were retrieved and evaluated for final inclusion. Of these, 190 56 were excluded for the following reasons: not a cost-of-illness study (n = 10); not an original research (n = 13); modelling studies (n= 8) and study conducted in high-income 191 countries (n = 25). The latest updated search identified two recent studies that were 192 193 included in the analyses.

Finally, 20 articles representing 17 individual studies were selected for this review.
Butman et al. [27] presented preliminary results of a study subsequently published by

Allegri et al. [28] ; similarly, the pilot study conducted by Ferretti et al. [29] in Brazil was completed and final results published by the same authors [30]. In both cases, only the final publications [28,30] were considered for the analyses. Jia et al. [31] and Yan et al. [32] presented different costs for the same cluster-randomized observational study in China, so their characteristics and results were merged.

201 Characteristics of included studies

202 Characteristics of the 17 included studies are summarized in Table 1. Out of 137 low-203 and middle-income countries, only 11 were represented in this review, including six 204 studies in China [31–37]; 2 in Brazil [30,38]; and one in each of the following countries: Argentina [28], Colombia [39], India [40], Iran [41], Peru [42], Philippines [43], Romania 205 [44], Thailand [45] and Turkey [46]. Our dataset covered all epidemiological regions of 206 the Global Burden of Disease, with the exception of Africa. Regional coverage was as 207 follow: 1 from Eastern Mediterranean [41]; 2 from South-East Asia [40,45]; 2 from 208 Europe [44,46]; 5 from the Americas [28,30,38,39,42] and 7 from Western Pacific [31-209 37,43]. Studies were conducted between 2003 and 2020. All studies performed a 210 retrospective collection of data in the previous 1-12 months, except studies from 211 Turkey [46] and Philippines [43], which added a 15-day and 5-year prospective data 212 collection pe riod on time spent in informal care, respectively. 213

The majority of studies focused on Alzheimer's Disease only (12/20), 5 studies included all types of dementia and the remaining four did not specify dementia subtypes in their study population. In almost all studies, case identification was based on a previous dementia diagnosis. A few updated or verified the diagnosis before inclusion in the studies. Disease definition followed standard criteria including ICD-10, DSM-IV-TR and/or NINCDS – ADRDA, plus various clinical or imaging investigations. Some studies excluded patients with mild cognitive impairment [29,30], early onset

dementia [41] or limited functional independence [42]. Only four studies reported the
mean disease duration: 2.7 years, 51.0 months, 60.1 months and 5.1 years in China
[34], Romania [44], Brazil [30] and Thailand [45] respectively.

The majority of studies examined all three categories of costs (direct medical, social 224 and informal care costs). Three studies [36,38,39] investigated only medical costs, 225 while Wang et al. [35] only looked at informal care costs. Zencir et al. [46] and Mould-226 227 Quevedo et al. [33] did not collect data on social and informal care costs respectively. Items included in each cost category varied widely. For direct medical costs, most 228 studies included outpatient, inpatient and medication costs. Some reported only 229 230 medication [30,38,39] or hospitalization [36] costs. Regarding medication costs for instance, Soares et al. [38] in Brazil reported the costs of dementia-specific drugs 231 dispensed by a government dispensing center. Meanwhile in Colombia, Prada et al. 232 233 [39] considered direct insurance reimbursement for all-condition drugs of dementia patients. In one study from China, Wang et al. [34] included the costs of official 234 dementia drugs, but also those of traditional medicine. Social care costs included travel 235 expenses and formal care services where appropriate, but also food expenses [31,41]. 236 With regard to informal care costs, most studies reported estimates of time spent on 237 238 care, without much detail on the activities considered. Two studies considered the patient loss-of-productivity [30,44] and one included the costs of health services for the 239 treatment of the caregiver [30]. Although the majority of studies valuated caregiver time 240 241 by the replacement cost methods (which assigns a monetary value to caregiver's time based on what it would cost to replace informal care activities with formal care), the 242 proxy used varied considerably, ranging from national minimum or average wage, to 243 the salary of a nurse in a public institution, or to the caregivers' salary. Table 2 provides 244 more details on the design characteristics of the included studies. 245

Results from the quality assessment of the studies are presented in Table 3. Almost 246 247 all studies provided basic information on the study design and population characteristics, such as objectives, sample size and demographics. Eight out of the 17 248 studies clearly indicated the cost estimate perspective. Only Allegri et al. [28] and 249 Custodio et al. [42] included a group of healthy participants in their sample, although 250 they did not use this information to calculate disease-specific net costs. Only the 251 252 cluster-randomized study in China presented the results of a sensitivity analysis [31,32]. Most studies (9/17) failed to present separate information on the number of 253 services used before getting in their valuation. Very few studies performed sensitivity 254 255 analyses to account for uncertainties in key indicators. Onetiu et al. [44] for instance estimated the cost of time spent on informal care by a replacement cost approach 256 using the national minimum wage, the average national wage and the caregiver's 257 258 salary. Finally, all studies presented and discussed methodological limitations.

259 Costs estimates

260 Annual costs of dementia per patient according to disease severity are summarized in Table 4. Annual domestic government health expenditures in 2020 for each country 261 are also shown in this table. Overall, in all costs categories, dementia costs tend to 262 increase with disease severity. Prada et al. [39] calculated the ratio of direct insurer 263 expense to mild stage at 1.62 for moderate and 4.87 for severe stages; i.e. compared 264 to a mild patient, a moderate stage patient will use 62% more resources and a severe 265 stage patient 387% more resources. Medical costs are generally highest in the mild 266 stage, while social costs (including institution fees) and informal care costs become 267 more important in the moderate and severe stages. Regardless of the disease stage, 268 we found a wide range of estimates of annual per patient costs in the studies. Medical 269 costs ranged from PPP\$131.0 in India [40] to PPP\$31,188.8 in China [45]; social costs 270

from PPP\$16.1 in Philippines [43] to PPP\$10,581.7 in China [31,32]; and informal care
costs from PPP\$140.0 in India [40] to PPP\$25,798 in China [45]. Overall, dementia
care can cost from PPP\$479.0 in India [40] to PPP\$66,143.6 in China [31,32] per year
for a single patient.

275 **DISCUSSION**

276 Findings

Studies included in this systematic review comprised 17 cost-of-illness studies on dementia in 11 LMICs across all GDB regions except Africa. These studies were conducted from 2003 to 2020 and focused mostly on Alzheimer's disease. All estimates of dementia costs increase with disease severity and informal care costs tend to exceed medical costs.

Globally, very few studies have been conducted to assess dementia costs worldwide. 282 About 10 years ago, Quentin et al. [47] reviewed cost-of-illness (COI) studies in Europe 283 and North America, including 28 studies. A review published in 2012 by Knapp et al. 284 [48] on the economic evaluation of dementia care identified only 29 individual studies. 285 Similarly, the international review of COI studies on dementia, by Schaller et al. in 2014 286 [49] found 27 individual studies for the period 2003 to 2012. Our review focusing on 287 LMICs included 17 studies. As reported by Hendriks et al. [50], beyond the complexity 288 of COI studies, the overriding constraint in LMICs is data availability, including lack of 289 accurate financial records and incomplete patient disease registers, as well as lack of 290 expertise to conduct cost studies. 291

292 Costs of dementia are high and highly variable. They range from PPP\$479.0 to 293 PPP\$66,143.6 per year for a single patient. These costs are colossal as families 294 remain the main bearers of the burden. Indeed, according to the WHO, in 2016, half of 295 the world's countries spent less than US\$350 per person annually on health-related

expenses, including most LMICs [51]. In 2018, the mean per capita general government domestic health expenditure was US\$134.7 in LMICs and US\$5,562.3 in HICs [52]. In this study, the per-patient costs of dementia reached fifty times these public expenditures.

Dementia costs increase with disease severity; similar results have been reported in 300 other studies and can be explained by the rise in care needs as dependence and 301 impairment increase [47,53,54]. Evidence from the United States suggests that 302 informal care costs decrease with disease severity as patients need more attention 303 and are therefore institutionalized [55]. This was not observed in this review, where 304 305 informal care costs remained the highest in most studies. Actually, in LMICs, about 95% of patients with dementia live with their families, compared to 69% in HICs [5]. 306 Thus, in these countries where universal health coverage is not achieved, families bear 307 308 the burden [56].

309 Limitations

The majority of included studies reported convenience sampling and/or small sample 310 size as a study limitation in their publications. Unfortunately, these two limitations 311 312 restrict further use of the results as they are difficult to generalize. Half of the included studies (9/17) focused on Alzheimer's Disease only, as this is the main pathology of 313 314 dementia. It should be noted that, the disease considered for cost evaluation and its 315 definition criteria strongly influence costs estimates. In fact, Custodio et al. reported that fronto-temporal dementia costs were higher than Alzheimer's Disease or vascular 316 dementia ones [42]. 317

Considering there is no standard methodology for cost-of-illness studies and no reference tool for quality assessment, available checklists [7,18] were adapted to assess the studies included in this review, which appeared to be of satisfactory quality.

However, very few studies included a detailed description of service utilization and a 321 322 clear definition of items considered in each cost category. The way in which services are defined and valuated is of crucial value in understanding and comparing the 323 resulting estimates, particularly in the context of LMICs where health care and health 324 financing systems vary. The lack of methodological standard in COI studies is a 325 common and challenging issue to address, as described in other reviews on dementia 326 327 [6,47,53]. It has also been described in other diseases, including colorectal cancer [8] and diabetes [57]. 328

Collection and valuation of time spent by caregivers on care is rather difficult. First, 329 330 many activities and services (activities of daily living and instrumental activities of daily living) are done for the older people regardless of their health status and are not 331 considered by caregivers as an additional workload, even when the person can no 332 333 longer perform them themselves. This is reinforced by the fact that many people still consider dementia to be a normal part of ageing [58]. Secondly, a joint effect should 334 be considered, that of achieving many activities simultaneously, such as shopping for 335 the PWD and caregiver themselves or supervising the PWD while cooking for the entire 336 337 household. According to monetary valuation, a good number of methods exist, with the 338 difficulties of disaggregating time spent (paid work time, domestic work and leisure time) and defining the unit cost to be applied to each category [22,59]. In the included 339 studies, both opportunity cost and proxy good approaches were used, but were not 340 sufficiently robust and/or their methods not well described. The quality of disease-341 specific costs estimates strongly rely on the accuracy of data collected and therefore 342 of the collection tools. Therefore, harmonizing the costs items definition and collection 343 is strongly recommended to ensure accuracy and comparability with other studies. 344 Standard collection tools exist, including the Resource Utilization in Dementia (RUD) 345

Instrument [20]. This is a dementia-specific tool that has been widely used and validated in global settings [60]. Otherwise, a minimum set of items should be collected, such as outpatient, inpatient and medication for medical costs, transport and accommodation for social costs. Attention should be paid to informal care time too, specifying which ADL, IADL or supervision activities were carried out, and how caregiving time was valued in money.

352 In addition, it was not always clearly stated in all studies which perspective was considered for the costs or whether these were dementia-specific or total patient costs. 353 Key distinctions that may affect the interpretation and use of costs. The majority of 354 355 studies presented estimates directly in US\$ or local currency. It was therefore necessary to know the precise cost reference date, exchange rate, country-specific 356 inflators and purchasing power parities to convert all estimates into international 357 358 dollars. This process allowed relevant comparisons of dementia costs between the studies included in this review. However, it limits comparisons with studies from other 359 settings or global estimates which usually present the results in US dollars. Due to the 360 wide heterogeneity of study designs, methodological and costing-related limitations 361 cited above, disease costs summaries provided in this review should be taken with 362 caution. 363

In this review, modelling studies were excluded. Modelling is a good way to appraise the reality without investing huge resources in complex field surveys. However, the likelihood of a model relies on the proxies used, for example, utilization of health services, market price of health services or reference wage for workers. These data are often neither standardized in resource-limited settings nor available [50]. As a result, many modelling studies may not provide an accurate picture of reality. Thus, in order to identify accurate methods for calculating dementia costs in LMICs, and to

summarize primary costs estimates, we considered only studies with field collection of 371 372 health services use and costs. Similarly, studies with a top-down cost approach were excluded as they did not include a direct measurement of dementia costs. Although 373 top-down studies are highly valuable, they mainly capture disease-specific medical 374 costs from the state or third party payer perspective, with very little information on 375 social and informal care costs. They also require a number of indicators like the number 376 of dementia cases or heath resource utilization, which may not be available in the 377 countries of interest, leading to the use of additional proxies and imputations. 378

Our search strategy included the most plausible sources of publications for the topic. The high rate of duplicates bears out the exhaustiveness of this review. In addition, no language or date restrictions were applied to the searches or results. Moreover, all studies that included cost estimation of any component of dementia care were included and all the costs estimates were converted from US dollars or local currency to purchasing power parity dollars to allow for cost comparisons between studies.

385 CONCLUSION

To the best of our knowledge, this is among the first reviews to focus on the cost of 386 387 dementia in LMICs. It is valuable regarding appraisal of methodological constraints when evaluating the costs of dementia in resource-limited settings. Findings 388 389 highlighted once more the scarcity of valuable cost-of-illness studies in these countries, 390 particularly in Africa where original research for primary data collection is essential. The costs of dementia were found to be high, placing an enormous burden on families. 391 These results should serve to raise the alarm on the urgency of dementia and to 392 393 advocate for dementia-oriented programs and policies.

394 ACKNOWLEDGEMENTS

- The authors would like to thank fellow colleagues from the Global Brain Health Institute (Fernando Aguzzoli-Peres, Naiara Demnitz and Yaohua Chen) and the Inserm U1094, IRD U270 – EpiMaCT research unit (Daniells Erazo) for their help in translating abstracts and articles in Portuguese, Chinese and Spanish identified during this systematic review.
- 400 No funds were received for this study.

401 **DISCLOSURE STATEMENT**

402 All the authors have no conflict of interest to declare.

REFERENCES

404	[1]	Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, Abdoli
405		A, Abualhasan A, Abu-Gharbieh E, Akram TT, Al Hamad H, Alahdab F, Alanezi
406		FM, Alipour V, Almustanyir S, Amu H, Ansari I, Arabloo J, Ashraf T, Astell-Burt
407		T, Ayano G, Ayuso-Mateos JL, Baig AA, Barnett A, Barrow A, Baune BT, Béjot
408		Y, Bezabhe WMM, Bezabih YM, Bhagavathula AS, Bhaskar S, Bhattacharyya K,
409		Bijani A, Biswas A, Bolla SR, Boloor A, Brayne C, Brenner H, Burkart K, Burns
410		RA, Cámera LA, Cao C, Carvalho F, Castro-de-Araujo LFS, Catalá-López F,
411		Cerin E, Chavan PP, Cherbuin N, Chu D-T, Costa VM, Couto RAS, Dadras O,
412		Dai X, Dandona L, Dandona R, De la Cruz-Góngora V, Dhamnetiya D, Dias da
413		Silva D, Diaz D, Douiri A, Edvardsson D, Ekholuenetale M, El Sayed I, El-Jaafary
414		SI, Eskandari K, Eskandarieh S, Esmaeilnejad S, Fares J, Faro A, Farooque U,
415		Feigin VL, Feng X, Fereshtehnejad S-M, Fernandes E, Ferrara P, Filip I, Fillit H,
416		Fischer F, Gaidhane S, Galluzzo L, Ghashghaee A, Ghith N, Gialluisi A, Gilani
417		SA, Glavan I-R, Gnedovskaya EV, Golechha M, Gupta R, Gupta VB, Gupta VK,
418		Haider MR, Hall BJ, Hamidi S, Hanif A, Hankey GJ, Haque S, Hartono RK,
419		Hasaballah AI, Hasan MT, Hassan A, Hay SI, Hayat K, Hegazy MI, Heidari G,
420		Heidari-Soureshjani R, Herteliu C, Househ M, Hussain R, Hwang B-F, Iacoviello
421		L, Iavicoli I, Ilesanmi OS, Ilic IM, Ilic MD, Irvani SSN, Iso H, Iwagami M,
422		Jabbarinejad R, Jacob L, Jain V, Jayapal SK, Jayawardena R, Jha RP, Jonas
423		JB, Joseph N, Kalani R, Kandel A, Kandel H, Karch A, Kasa AS, Kassie GM,
424		Keshavarz P, Khan MA, Khatib MN, Khoja TAM, Khubchandani J, Kim MS, Kim
425		YJ, Kisa A, Kisa S, Kivimäki M, Koroshetz WJ, Koyanagi A, Kumar GA, Kumar
426		M, Lak HM, Leonardi M, Li B, Lim SS, Liu X, Liu Y, Logroscino G, Lorkowski S,
427		Lucchetti G, Lutzky Saute R, Magnani FG, Malik AA, Massano J, Mehndiratta

MM, Menezes RG, Meretoja A, Mohajer B, Mohamed Ibrahim N, Mohammad Y, 428 429 Mohammed A, Mokdad AH, Mondello S, Moni MAA, Moniruzzaman M, Mossie TB, Nagel G, Naveed M, Nayak VC, Neupane Kandel S, Nguyen TH, Oancea B, 430 Otstavnov N, Otstavnov SS, Owolabi MO, Panda-Jonas S, Pashazadeh Kan F, 431 Pasovic M, Patel UK, Pathak M, Peres MFP, Perianayagam A, Peterson CB, 432 Phillips MR, Pinheiro M, Piradov MA, Pond CD, Potashman MH, Pottoo FH, 433 Prada SI, Radfar A, Raggi A, Rahim F, Rahman M, Ram P, Ranasinghe P, Rawaf 434 DL, Rawaf S, Rezaei N, Rezapour A, Robinson SR, Romoli M, Roshandel G, 435 Sahathevan R, Sahebkar A, Sahraian MA, Sathian B, Sattin D, Sawhney M, 436 437 Saylan M, Schiavolin S, Seylani A, Sha F, Shaikh MA, Shaji K, Shannawaz M, Shetty JK, Shigematsu M, Shin JI, Shiri R, Silva DAS, Silva JP, Silva R, Singh 438 JA, Skryabin VY, Skryabina AA, Smith AE, Soshnikov S, Spurlock EE, Stein DJ, 439 Sun J, Tabarés-Seisdedos R, Thakur B, Timalsina B, Tovani-Palone MR, Tran 440 BX, Tsegaye GW, Valadan Tahbaz S, Valdez PR, Venketasubramanian N, 441 Vlassov V, Vu GT, Vu LG, Wang Y-P, Wimo A, Winkler AS, Yadav L, 442 Yahyazadeh Jabbari SH, Yamagishi K, Yang L, Yano Y, Yonemoto N, Yu C, 443 Yunusa I, Zadey S, Zastrozhin MS, Zastrozhina A, Zhang Z-J, Murray CJL, Vos 444 445 T (2022) Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. 446 Lancet Public Health 7, e105–e125. 447

World Health Organization, Dementia statistics, Last updated 20 September
2022, https://www.who.int/news-room/fact-sheets/detail/dementia, Accessed on
2022-10-27.

451 [3] World Health Organization (2021) *Global status report on the public health* 452 *response to dementia*, World Health Organisation, Geneva, Switzerland.

- 453 [4] Wimo A, Ali G-C, Guerchet M, Prince M, Prina M, Wu Y-T, Alzheimer's Disease
 454 International (2015) World Alzheimer Report 2015: The global impact of
 455 dementia: An analysis of prevalence, incidence, cost and trends, Alzheimer's
 456 Disease International (ADI), London.
- 457 [5] Wimo A, Gauthier S, Prince M (2018) *Global estimates of informal care*,
 458 Alzheimer's Disease International (ADI), London.
- 459 [6] Bloom BS, de Pouvourville N, Straus WL (2003) Cost of illness of Alzheimer's
 460 disease: how useful are current estimates? *The Gerontologist* 43, 158–164.
- 461 [7] Larg A, Moss JR (2011) Cost-of-illness studies: a guide to critical evaluation.
 462 *PharmacoEconomics* 29, 653–671.
- 463 [8] Ó Céilleachair AJ, Hanly P, Skally M, O'Neill C, Fitzpatrick P, Kapur K, Staines
 464 A, Sharp L (2013) Cost comparisons and methodological heterogeneity in cost-
- of-illness studies: the example of colorectal cancer. *Med Care* **51**, 339–350.
- 466 [9] Bloom BS, Bruno DJ, Maman DY, Jayadevappa R (2001) Usefulness of US cost467 of-illness studies in healthcare decision making. *PharmacoEconomics* 19, 207–
 468 213.
- 469 [10] Kenigsberg P-A, Ersek K, Gulácsi L, Karpati K, Jacques A, Gustavsson A,
- Jönsson L, Mcdaid D, Valtonen H, Wimo A (2009) Impact socio-économique de
 la maladie d'Alzheimer et des maladies apparentées en Europe. *Gerontol Soc*32 / n° 128-129, 297–318.
- [11] Colucci L, Bosco M, Fasanaro AM, Gaeta GL, Ricci G, Amenta F (2014)
 Alzheimer's disease costs: what we know and what we should take into account.
- 475 *J Alzheimers Dis JAD* **42**, 1311–1324.

- 476 [12] Wimo A, Prince M (2010) *World Alzheimer Report 2010: The Global Economic*477 *Impact of Dementia*, Published by Alzheimer's Disease International (ADI) 21
 478 September 2010, Reprinted June 2011, London.
- 479 [13] Guerchet M, Mayston R, Lloyd-Sherlock P, Prince M, Aboderin I, Akinyemi R,
 480 Paddick S-M, Wimo A, Amoakoh-Coleman M, Uwakwe R, Ezeah P (2017)
- 481 Dementia in sub-Saharan Africa: Challenges and opportunities, Alzheimer
 482 Disease International, London.
- 483 [14] World Bank, Low & middle income countries | Data.
 484 https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-

485 bank-country-and-lending-groups. Accessed on 2022-01-18.

- 486 [15] Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web
 487 and mobile app for systematic reviews. *Syst Rev* 5, 210.
- Interview [16] Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015)
 Methods for the Economic Evaluation of Health Care Programmes, Oxford
 University Press.
- [17] Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D,
 Augustovski F, Briggs AH, Mauskopf J, Loder E, CHEERS Task Force (2013)
 Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
 statement. *Value Health J Int Soc Pharmacoeconomics Outcomes Res* 16, e15.
- [18] Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rössler W (2014)
 Cost of illness for bipolar disorder: a systematic review of the economic burden. *Bipolar Disord* 16, 337–353.
- 499 [19] Jo C (2014) Cost-of-illness studies: concepts, scopes, and methods. *Clin Mol*500 *Hepatol* **20**, 327–337.

[20] Wimo A, Wetterholm AL, Mastey V, Winblad B (1998) Evaluation of the resource
utilization and caregiver time in Anti-dementia drug trials – a quantitative battery.
In *The Health Economics of Dementia* John Wiley & Sons, London, p. 576.

- [21] Koopmanschap MA, van Exel NJA, van den Berg B, Brouwer WBF (2008) An
 Overview of Methods and Applications to Value Informal Care in Economic
 Evaluations of Healthcare. *PharmacoEconomics* 26, 269–280.
- 507 [22] Oliva-Moreno J, Trapero-Bertran M, Peña-Longobardo LM, Del Pozo-Rubio R
 508 (2017) The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic
 509 Review. *PharmacoEconomics* 35, 331–345.
- 510 [23] World Bank, Official exchange rate (LCU per US\$, period average) | Data.
 511 https://data.worldbank.org/indicator/PA.NUS.FCRF, Accessed on 2022-01-18.
- 512 [24] World Bank, Inflation, GDP deflator (annual %) | Data.
 513 https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG. Accessed on 2022514 01-18.
- 515 [25] World Bank, PPP conversion factor, GDP (LCU per international \$) | Data.
 516 https://data.worldbank.org/indicator/PA.NUS.PPP. Accessed on 2022-01-18.
- [26] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD,
 Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw
 JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S,
 McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher
 D (2021) The PRISMA 2020 statement: an updated guideline for reporting
 systematic reviews. *BMJ* 372, n71.
- 523 [27] Butman J, Sarasola D, Lon L, Serrano C, Arizaga R, Taragano FE, Manes F, 524 Casanuovo A, Machnicki G, Allegri RF (2003) Impacto económico de la

- 525 enfermedad de Alzheimer: Resultados preliminares en Buenos Aires. *Rev*526 *Neurol Argent* 28, 16–23.
- [28] Allegri RF, Butman J, Arizaga RL, Machnicki G, Serrano C, Taragano F, E o,
 Sarasola D, Lon L, ro (2007) Economic impact of dementia in developing
 countries: an evaluation of costs of Alzheimer-type dementia in Argentina. *Int Psychogeriatr* 19, 705–718.
- [29] Ferretti CEL, Nitrini R, Brucki SMD (2015) Indirect cost with dementia: A Brazilian
 study. *Dement Neuropsychol* 9, 42–50.
- [30] Ferretti C, Sarti FM, Nitrini R, Ferreira FF, Brucki SMD (2018) An assessment of
 direct and indirect costs of dementia in Brazil. *PloS One* **13**, e0193209.
- [31] Jia J, Wei C, Chen S, Li F, Tang Y, Qin W, Zhao L, Jin H, Xu H, Wang F, Zhou
- A, Zuo X, Wu L, Han Y, Han Y, Huang L, Wang Q, Li D, Chu C, Shi L, Gong M,
- 537 Du Y, Zhang J, Zhang J, Zhou C, Lv J, Lv Y, Xie H, Ji Y, Li F, Yu E, Luo B, Wang
- 538 Y, Yang S, Qu Q, Guo Q, Liang F, Zhang J, Tan L, Shen L, Zhang K, Zhang J,
- 539 Peng D, Tang M, Lv P, Fang B, Chu L, Jia L, Gauthier S (2018) The cost of
- 540 Alzheimer's disease in China and re-estimation of costs worldwide. *Alzheimers* 541 *Dement J Alzheimers Assoc* **14**, 483–491.
- [32] Yan X, Li F, Chen S, Jia J (2019) Associated Factors of Total Costs of
 Alzheimer's Disease: A Cluster-Randomized Observational Study in China. J
 Alzheimers Dis JAD 69, 795–806.
- [33] Mould-Quevedo JF, Tang B, Harary E, Kurzman R, Pan S, Yang J, Qiao J (2013)
 The burden of caring for dementia patients: caregiver reports from a crosssectional hospital-based study in China. *Expert Rev Pharmacoecon Outcomes Res* 13, 663–673.

549	[34]	Wang G, Cheng Q, Zhang S, Bai L, Zeng J, Cui P-J, Zhang T, Sun Z-K, Ren R-
550		J, Deng Y-L, Xu W, Wang Y, Chen S-D (2008) Economic impact of dementia in
551		developing countries: an evaluation of Alzheimer-type dementia in Shanghai,
552		China. J Alzheimers Dis JAD 15, 109–115.

- [35] Wang H, Gao T, Wimo A, Yu X (2010) Caregiver Time and Cost of Home Care
 for Alzheimer's Disease: A Clinic-based Observational Study in Beijing, China. *Ageing Int* 35, 153–165.
- [36] Zhang H, Zhang D, Yin Y, Zhang C, Huang Y (2019) Costs of Hospitalization for
 Dementia in Urban China: Estimates from Two Urban Health Insurance Scheme
 Claims Data in Guangzhou City. *Int J Environ Res Public Health* 16,2781.
- [37] XiaoJuan G, Yan Q, SuHang S, QiuMin Q (2019) Investigation on the economic
 burden and its influencing factors of Alzheimer's disease in Xi'an. *Pract Geriatr*33, 449–452.
- [38] Soares NM, Pereira GM, Figueiredo RI da N, Soares NM, Almeida RMM de,
 Portela A da S (2017) Economic impact and prevalence of Alzheimer's Disease
 in a Brazilian capital. *Impacto Econ E Prevalencia Doenca Alzheimer Em Uma Cap Bras* 10, 133–138.
- [39] Prada SI, Takeuchi Y, Merchán-Galvis AM, Ariza-Araújo Y (2017) Actual
 expense associated with patients with Alzheimer's disease in Colombia. Int
 Psychogeriatr 29, 1835–1840.
- [40] Malapur PU, Kumar N, Khandelwal SK, Tripathi M (2021) Cost of Illness of Major
 Neurocognitive Disorders in India. *Neurol India* 69, 1265.
- 571 [41] Aajami Z, Kebriaeezadeh A, Nikfar S (2019) Direct and indirect cost of managing
 572 Alzheimer's disease in the Islamic Republic of Iran. *Iran J Neurol* 18, 7–12.

[42] Custodio N, Lira D, Herrera-Perez E, Del Prado LN, Parodi J, Guevara-Silva E,
 Castro-Suarez S, Montesinos R (2015) Cost-of-illness study in a retrospective
 cohort of patients with dementia in Lima, Peru. *Dement Neuropsychol* 9, 32–41.

- [43] Dominguez J, Jiloca L, Fowler KC, De Guzman MF, Dominguez-Awao JK,
 Natividad B, Domingo J, Dominguez JD, Reandelar M, Ligsay A, Yu JR, Aichele
 S, Phung TKT (2021) Dementia Incidence, Burden and Cost of Care: A Filipino
 Community-Based Study. *Front Public Health* 9, 628700.
- [44] Onetiu V, Aurelian SM, Capisizu A, Cristescu F, Zus IC, Kissimova-Skarbek K
 (2016) Cost of dementia in Romania: a cross-sectional Cost-of-Illness study
 undertaken in Bucharest. *Zdr Publiczne Zarządzanie* 2016, 204–226.
- [45] Kongpakwattana K, Dejthevaporn C, Krairit O, Dilokthornsakul P, Mohan D,
 Chaiyakunapruk N (2019) A Real-World Evidence Analysis of Associations
 Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer's
 Disease in Thailand. *Value Health J Int Soc Pharmacoeconomics Outcomes Res*22, 1137–1145.
- [46] Zencir M, Kuzu N, Beşer NG, Ergin A, Catak B, Sahiner T (2005) Cost of
 Alzheimer's disease in a developing country setting. *Int J Geriatr Psychiatry* 20,
 616–622.
- [47] Quentin W, Riedel-Heller SG, Luppa M, Rudolph A, König H-H (2010) Cost-ofillness studies of dementia: a systematic review focusing on stage dependency
 of costs. *Acta Psychiatr Scand* 121, 243–259.
- [48] Knapp M, Iemmi V, Romeo R (2013) Dementia care costs and outcomes: a
 systematic review. *Int J Geriatr Psychiatry* 28, 551–561.


[49] Schaller S, Mauskopf J, Kriza C, Wahlster P, Kolominsky-Rabas PL (2015) The
main cost drivers in dementia: a systematic review. *Int J Geriatr Psychiatry* 30,
111–129.

- [50] Hendriks ME, Kundu P, Boers AC, Bolarinwa OA, te Pas MJ, Akande TM,
 Agbede K, Gomez GB, Redekop WK, Schultsz C, Tan SS (2014) Step-by-step
 guideline for disease-specific costing studies in low- and middle-income
 countries: a mixed methodology. *Glob Health Action* 7,.
- [51] Xu K, Soucat A, Kutzin J, Brindley C, Vande Maele N, Touré H, Aranguren Garcia
 M, Li D, Barroy H, Flores G, Roubal T, Indikadahena C, Cherilova V (2018) *Public Spending on Health: A Closer Look at Global Trends*, World Health Organisation,
 Geneva.
- [52] World Bank, Domestic general government health expenditure per capita, Last
 updated 2020, Accessed on 18 January 2022.
- [53] Jönsson L, Wimo A (2009) The cost of dementia in Europe: a review of the
 evidence, and methodological considerations. *PharmacoEconomics* 27, 391–
 403.
- [54] Luppa M, Heinrich S, Matschinger H, Hensel A, Luck T, Riedel-Heller SG, König
 H-H (2008) Direct costs associated with mild cognitive impairment in primary
 care. *Int J Geriatr Psychiatry* 23, 963–971.
- [55] Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, Covinsky KE (2002)
 Patient and caregiver characteristics and nursing home placement in patients
 with dementia. *JAMA* 287, 2090–2097.
- [56] Ferri CP, Jacob KS (2017) Dementia in low-income and middle-income
 countries: Different realities mandate tailored solutions. *PLoS Med* 14,
 e1002271.

621	[57]	Pagano E, Brunetti M, Tediosi F, Garattini L (1999) Costs of diabetes. A
622		methodological analysis of the literature. <i>PharmacoEconomics</i> 15 , 583–595.

- [58] Cations M, Radisic G, Crotty M, Laver KE (2018) What does the general public
 understand about prevention and treatment of dementia? A systematic review of
 population-based surveys. *PloS One* **13**, e0196085.
- [59] Oliva-Moreno J, Peña-Longobardo LM, García-Mochón L, Del Río Lozano M,
 Mosquera Metcalfe I, García-Calvente MDM (2019) The economic value of time
 of informal care and its determinants (The CUIDARSE Study). *PloS One* 14,
 e0217016.
- [60] Wimo A, Gustavsson A, Jönsson L, Winblad B, Hsu M-A, Gannon B (2013)
 Application of Resource Utilization in Dementia (RUD) instrument in a global
 setting. *Alzheimers Dement* 9, 429-435.e17.

Figure 1: Articles selection flow diagram



Adapted from: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

Table 1: General characteristics of included studies

					Sample	Mean age	Male	Disease	Disease severity stages (%)			
Study	Country	Study period	Settings	Dementia subtype	size	(years)	percentage	severity criteria	Mild	Moderate	Severe	
Aajami et al., [41]	Iran	2017	Urban only	Alzheimer's disease	300	80.0	48.0	MMSE	33.3	33.3	33.3	
Allegri et al., [28]	Argentina	NS	Urban only	Alzheimer's disease	125	74.6	19.2	MMSE	48.0	30.0	22	
Custodio et al., [42]	Peru	2012 - 2013	Urban only	All types of dementia	106	70.0	39.7	None		NA		
Dominguez et al., [43]	Philippines	2015-2016	Urban & rural	All types of dementia	81	73.8	25.9	None		NA		
Ferretti et al., [30]	Brazil	2011 - 2015	Urban only	Dementia not specified	156	72.9	41.7	FAST Scale	29.1	47.5	13.4	
Kongpakwattana et al., [45]	Thailand	2017 - 2018	Urban only	Alzheimer's disease	148	80.1	29.1	MMSE	23.6	39.9	36.5	
Malapur et al., [40]	India	NS	Urban & rural	Major Neurocognitive Disorders	50	68.6	60.0	CDR		46	54	
Mould-Quevedo et al., [33]	China	2009	Urban only	Dementia not specified	1,387	67.6	52.0	None		NA		
Onetiu et al., [44]	Romania	2013 - 2014	Urban only	Dementia not specified	31	NS	NS	NS	29.0	45.2	25.8	
Prada et al., [39]	Colombia	2011 - 2013	Urban & rural	All types of dementia	340	NS	43.0	Drug dispensed	36.1**	44.5**	12.9**	
Soares et al., [38]	Brazil	2014	Urban only	Alzheimer's disease	855	78.7	30.6	None		NA		
Wang et al., [34]	China	2005-2006	Urban only	Alzheimer's disease	66	74.0	34.8	MMSE	19.7	56.1	24.2	
Wang et al., [35]	China	2008 - 2009	Urban only	Alzheimer's disease	79	NS	21.5	MMSE	25.4	60.6	14.0	
XiaoJuan et al., [37]	China	2016 - 2018	Urban & rural	Alzheimer's disease	119	70.8	38.1	MMSE	7.6	67.23	25.2	
Jia et al., Yan et al., [31,32]	China	2015 - 2016	Urban & rural	Alzheimer's disease	3,046	75.3	45.8	MMSE	18.7	49.3	32.0	
Zencir et al., [46]	Turkey	2003	Urban only	Alzheimer's disease	42	70.5	38.1	MMSE	42.9	16.7	40.4	
Zhang et al., [36]	China	2008 - 2013	Urban only	All types of dementia	5,747	77.4	42.8	None		NA		

**Study reported 6.5% of the population with an undefined disease severity stage; CDR: clinical dementia rating scale; FAST: Functional Assessment Staging Tool; MMSE: Mini Mental State Examination; NA: not applicable; NS: not specified.

Cturdu.	Dat	a so	urce	Perspective	e Type of costs Costs categories		Costs collection tools	Caregiver time valuation		
Study	MR	PI	HI			considered				
Aajami et al., [41]	+	+	-	Societal	UN	Medical – Social – Informal	DQ; self-report checklist	Human capital approach		
Allegri et al., [28]	-	+	-	UN	Gross	Medical – Social – Informal	Adapted 10/66 group questionnaire	Replacement costs; MW		
Custodio et al., [42]	+	+	-	UN	Gross	Medical – Social – Informal	ZBI; DQ	Replacement costs; MW		
Dominguez et al.,[43]	-	+	-	UN	Gross	Medical – Social – Informal	NS	Opportunity costs		
Ferretti et al., [30]	-	+	-	Societal	Net	Medical – Social – Informal	ZBI; RUD instrument; DQ	Replacement costs; MW		
Kongpakwattana et al., [45]	+	+	-	Societal	Gross	Medical – Social – Informal	RUD Instrument	Opportunity costs		
Malapur et al., [40]	-	+	-	UN	Gross	Medical – Social – Informal	DQ	Human capital approach		
Mould-Quevedo et al., [33]	-	+	-	UN	UN	Medical - Social	ZBI; DQ	NA		
Onetiu et al., [44]	+	+	+	Societal	Gross	Medical – Social – Informal	Modified RUD Instrument	Opportunity costs		
Prada et al., [39]	-	-	+	Third party	Net	Medical	None	NA		
Soares et al., [38]	+	-	-	UN	Net	Medical	None	NA		
Wang et al., [34]	-	+	-	UN	UN	Medical – Social – Informal	DQ	Replacement costs; MW		
Wang et al., [35]	-	+	-	UN	Gross	Informal	RUD Instrument	Replacement costs; average employment income		
XiaoJuan et al., [37]	-	+	-	Societal	Gross	Medical – Social – Informal	DQ	NS		
Jia et al, Yan et al., [31,32]	+	+	-	UN	Gross	Medical – Social – Informal	DQ	NS		
Zencir et al., [46]	-	+	-	Societal	Gross	Medical - Informal	DQ; daily time sheets	Replacement costs; wage of a nurse in a public institution		
Zhang et al., [36]	-	-	+	Healthcare system	Gross	Medical	None	NA		

Table 2: Design characteristics of costs estimations

DQ: designed questionnaire; HI: health insurance; MR: medical records; MW: minimum wage; NA: not applicable; NS: not specified; PI: patient interview; RUD: Resource utilization in dementia questionnaire; UN: unclear; ZBI: Zarit burden interview; +: yes; -: no

Table 3: Quality assessment of included studies

Criteria	Aajami et al, [41]	Allegri et al [28]	Custodio et al, [42]	Dominguez et al., [43]	Ferretti et al, [30]	Kongpakwattana et al, [45]	Malapur et al., [40]	Mould-Quevedo et al, [33]	Onetiu et al, [44]	Prada et al, [39]	Soares et al, [38]	Wang et al, [34]	Wang et al, [35]	XiaoJuan et al [37]	Jia et al, Yan et al, [31,32]	Zencir et al, [46]	Zhang et al, [36]
Aims and methods of the study																	
Study objective	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Inclusion and exclusion	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Non-diseased comparison group or disease-related costs	-	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Matching or regression analysis	na	-	na	na	na	na	na	na	na	na	na	na	na	na	na	na	na
Sensitivity analysis	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
Costs calculation																	
Data source	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Perspective	+	(+)	-	-	+	+	(+)	(+)	+	+	(+)	(+)	(+)	+	(+)	+	(+)
Cost calculation	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+	+	+
Cost categories	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+
Reference (price) year	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	-
Currency	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+	+
Exchange rate	+	+	+	+	+	+	-	+	-	+	-	+	+	-	+	-	+
Inflation and/or discount rates	na	-	-	-	-	-	na	na	-	+	na	-	-	-	-	na	-
Monetary valuation of resource utilisation	-	-	+	+	+	+	+	+	+	-	-	+	+	-	+	+	-
Valuation method	na	na	+	+	+	+	+	-	+	na	na	+	+	na	-	+	na
Presentation of results																	
Sample size	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Demographics	+	+	+	+	+	+	+	+	+	-	+	+	+	+	+	+	+
Arithmetic mean costs	+	+	+*	+*	+	+	+	+	+	+	+	+	+	+	+	+	+
Standard deviations	+	-	+*	+*	+	+	-	-	+	-	-	+	+	+	-	+	+
Separate information number of services used	-	+	+	-	+	+	-	-	+	-	-	-	+	-	-	-	+
Discussion																	
Discussion with respect to other results	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
Uncertainties	-	-	+	-	-	-	-	+	+	-	-	+	+	-	+	+	+
Limitations	+	-	+	+	+	+	+	+	+	+	+	+	+	-	+	+	+

+: yes, clearly presented in the article; (+): not clearly presented; -: no, not described; na: not applicable; *median and interquartile range

	N	/lild disea	se	Мос	Moderate disease			evere disea	ase		Expen		
Study	Medical	social	Informal	Medical	Social	Informal	Medical	Social	Informal	Medical	Social	Informal	diture [#]
Aajami et al., [41]	498.6	766.9	0	638.6	1869.1	1320.9	2046.9	3665.2	1519.2	1060.3	2098.3	945.7	222.4
Allegri et al., [28]	8146.8	664.6	4792.1	7993.3	3813.7	5281.4	10113.9	14765.4	4082.5	8533.5	4711.5	4782.5	1,221.8
Custodio et al., [42]	-	-	-	-	-	-	-	-	-	8216.7	-	4878.1	551.2
Dominguez et al.,[43]	-	-	-	-	-	-	-	-	-	582.7	16.1	8958.9	128.6
Ferretti et al., [30]	1798.6	392.4	12115.5	1828.2	173.6	23588.2	2209.6	0.0	13198.9	1688.1	196.5	16492.5	637.9
Kongpakwattana et al., [45]	24730.5	3998.0	16860.9	33423.0	8690.8	22276.8	32933.6	13008.2	35440.2	31188.8	9156.3	25798.5	480.0
Malapur et al.,[40]	-	-	-	63.6	32.4	200.4	188.4	357.8	89.2	131.0	208.0	140.0	74.2
Mould-Quevedo et al., [33]	-	-	-	-	-	-	-	-	-	8844.0	4129.0	-	527.6
Onetiu et al., [44]	3868.8	4748.5	5108.6	2126.2	6387.0	6293.9	5658.3	12132.0	7199.3	3542.8	7394.0	6183.7	1,256.2
Prada et al., [39]	2061.7	-	-	3336.2	-	-	10049.2	-	-	4210.0	-	-	827.4
Soares et al., [38]	-	-	-	-	-	-	-	-	-	448.9	-	-	637.9
Wang et al., [34]	1562.8	829.1	1363.5	1614.6	781.5	2733.8	1814.3	893.8	5344.6	1652.7	818.1	3095.7	427.6
Wang et al., [35]	-	-	13107.8	-	-	19998.7	-	-	45254.1	-	-	21808.8	427.6
XiaoJuan et al., [37]	4062.7	2272.6	-	4618.1	3569.5	-	4226.8	7305.2	-	4477.5	4413.2	-	427.6
Jia et al, Yan et al., [31,32]	-	-	-	-	-	-	-	-	-	26339.0	10581.7	20865.8	427.6
Zencir et al., [46]	5280.9	-	472.7	7738.8	-	4785.4	7794.2	-	8084.3	6706.8	-	4268.0	906.0
Zhang et al., [36]	-	-	-	-	-	-	-	-	-	2944.6	-	-	427.6

Table 4: Annual costs of dementia per patient according to the disease severity stage (PPP\$ 2020)

Public expenditure on health from domestic sources per capita expressed in international dollars at purchasing power parity (PPP time series based on ICP2011 PPP). Source: World Bank https://data.worldbank.org/indicator/SH.XPD.GHED.PP.CD

SUPPLEMENTARY MATERIALS

Supplementary material 1: Search strategy

(performed: 2nd March, 2020; updated: December 28th 2021)

EconLit; Ovidsp (Pubmed/Medline, Embase, global Health, PsycInfo, PsycARTICLES); Scopus (search in abstract field); Web of science; ProQuest (search in abstract field).

(dement* OR Alzheim* OR "cognitive impairment" OR "cognitive dysfunction" OR "cognitive decline" OR "cognitive disorder" OR "memory loss" OR "memory disorder") AND (cost* OR econom* OR "cost of illness" OR "cost analysis" OR "valuation" OR "expenditure" OR "budget" OR financ* OR fund* OR "payment") AND ("Afghanistan" OR "Albania" OR "Algeria" OR "American Samoa" OR "Angola" OR "Armenia" OR "Azerbaijan" OR "Bangladesh" OR "Belarus" OR "Belize" OR "Benin" OR "Bhutan" OR "Bolivia" OR "Bosnia and Herzegovina" OR "Botswana" OR "Brazil" OR "Bulgaria" OR "Burkina Faso" OR "Burundi" OR "Cape Verde" OR "Cambodia" OR "Cameroon" OR "Central African Republic" OR "Chad" OR "China" OR "Colombia" OR "Comoros" OR "Congo Democratic" OR "Congo" OR "Costa Rica" OR "Cuba" OR "Djibouti" OR "Dominica" OR "Dominican Republic" OR "Ecuador" OR "Egypt" OR "El Salvador" OR "Equatorial Guinea" OR "Eritrea" OR "Ethiopia" OR "Fiji" OR "Gabon" OR "Gambia" OR "Georgia" OR "Ghana" OR "Grenada" OR "Guatemala" OR "Guinea" OR "Guinea Bissau" OR "Guyana" OR "Haiti" OR "Honduras" OR "Ivory Coast" OR "India" OR "Indonesia" OR "Iran" OR "Iraq" OR "Jamaica" OR "Jordan" OR "Kazakhstan" OR "Kenya" OR "Kiribati" OR "Korea" OR "Kosovo" OR "Kyrgyz Republic" OR "Lao PDR" OR "Lebanon" OR "Lesotho" OR "Liberia" OR "Libya" OR "Macedonia" OR "Madagascar" OR "Malawi" OR "Malaysia" OR "Maldives" OR "Mali" OR "Marshall

Islands" OR "Mauritania" OR "Mauritius" OR "Mexico" OR "Micronesia" OR "Moldova" OR "Mongolia" OR "Montenegro" OR "Morocco" OR "Mozambique" OR "Myanmar" OR "Namibia" OR "Nauru" OR "Nepal" OR "Nicaragua" OR "Niger" OR "Nigeria" OR "Pakistan" OR "Papua New Guinea" OR "Paraguay" OR "Peru" OR "Philippines" OR "Romania" OR "Russian Federation" OR "Rwanda" OR "Samoa" OR "Sao Tome and Principe" OR "Senegal" OR "Serbia" OR "Sierra Leone" OR "Solomon Islands" OR "Somalia" OR "South Africa" OR "South Sudan" OR "Sri Lanka" OR "St Lucia" OR "St Vincent and the Grenadines" OR "Sudan" OR "Suriname" OR "Swaziland" OR "Syrian Arab Republic" OR "Tajikistan" OR "Tanzania" OR "Thailand" OR "Timor-Leste" OR "Uganda" OR "Ukraine" OR "Uzbekistan" OR "Vanuatu" OR "Venezuela" OR "Vietnam" OR "West Bank and Gaza" OR "Yemen" OR "Zambia" OR "Zimbabwe" OR "developing" OR "Iow income" OR "middle income" OR "intermediate income" OR "resource limited")

Google scholar (first 200 results only)

(dementia OR Alzheimer OR "cognitive impairment" OR "cognitive disorder" OR "memory disorder") AND (cost OR economy OR "valuation" OR "expenditure") AND ("low income" OR "middle income" OR "intermediate income" OR "resource limited")

Greylit, Georgetown resources

Keywords: dementia, Alzheimer, cognitive impairment, cost of illness, cost of care, low and middle income countries

List of all 137 countries considered as LMICs by World Bank on January 1st, 2020

Supplementary material 2: Explanation of quality criteria

Criterion	Description
Aims and methods	
Study objective	The objective(s) and research question(s) of the study was
	(were) described clearly
Inclusion and exclusion	At least the objective diagnostic criteria (e.g., ICD code and
	DSM-IV) used to identify eligible patients were reported. The
	study population was specified
Non-diseased comparison	The study included a non-diseased control group in order to
group or disease-related	calculate excess costs or, if no control group was involved, the
costs	costs were due to the disease of interest
Matching or regression	If comparison groups were used: a) they were matched, at least
analysis	in terms of age and/or gender, to allow a direct comparison
	between equally dispersed groups with regard to their
	characteristics or b) regression analysis was carried out in order
	to control for differences
Sensitivity analyses	Relevant parameters were varied in univariate and/or
	probabilistic sensitivity analyses in order to address parameter
	uncertainties (e.g., different unit costs)
Calculation of costs	
Data source	The source of information on healthcare utilization or costs was
	reported and mentioned specifically
Perspective	The perspective of the cost calculation was reported (e.g., from
	payer, employer, or societal perspective)
Cost calculation	The method of cost calculation was clearly documented
Cost categories	The study estimated costs from the utilization of different kinds
	of healthcare services or areas, which meant that more than one
	category was given, in order to consider, at best, all costs that
	accrued from the disease under study
Reference year (price)	All costs were valued at the price level of a stated base year
Currency	The currency in which the costs were calculated was reported

Inflation rate and/or	If data were collected from or estimated for a period longer than
discount rate	one year, costs were adjusted for differential timing and the
	inflation rate/discount rate was mentioned
Monetary valuing of	If data on resource utilization were collected that were valued
resource utilization	with unit costs, the latter were reported; if cost data were used,
	these reflected actual charges
Presentation of results	
Sample size	The sample size was reported
Demographics	The characteristics of the sample were described; at least
	(mean) age and gender were reported
Arithmetic mean costs	The cost estimates were (partly) presented as arithmetic means
Standard deviations	Standard deviations of cost estimates were (partly) reported as a
	measure of variability
Separate information of	Separate information about the number of (health) services and
used number of services	cost were given for all cost categories that were described
and costs	
Discussion	
Discussion with respect to	The results were discussed in relation to other studies on the
other studies	same topic
Uncertainties	Was uncertainty around the estimates and its implications
	adequately discussed
Limitations	The limitations regarding the calculation of costs and the
	representativeness of the study population, in particular, were
	discussed in detail

Source: Larg A, Moss JR (2011) Cost-of-illness studies: a guide to critical evaluation. *PharmacoEconomics* **29**, 653–671. & Kleine-Budde K, Touil E, Moock J, Bramesfeld A, Kawohl W, Rössler W (2014) Cost of illness for bipolar disorder: a systematic review of the economic burden. *Bipolar Disord* **16**, 337–353.

Sources	Number of results
Indexed databases	
Econlit	25
Embase (via ovidsp)	2,708
Global health (via ovidsp)	283
PsycARTICLES (via ovidsp)	2,475
PsycInfo (via ovidsp)	809
PubMed/Medline (via ovidsp)	1,340
Scopus (search in abstract field)	1,387
Web of science (via Insermbiblio)	1,471
Grey literature	
Georgetown University resources	0
Google scholar (first 200 results)	200
Greylit	0
ProQuest (search in abstract field)	470
Overall	11,168

Supplementary material 3: search results